Catalogue Number: AB00449-13.0-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | Fibronectin receptor; CD49 antigen-like family member E; Integrin alpha-F; VLA-5; CD49e. |
| Shipping Condition: | Blue Ice |
| Unit(s): | 200 ug |
| Host name: | Human |
| Clone: | M200 (Volociximab) |
| Isotype: | IgG4 |
| Immunogen: | Heterodimeric α5β1Fc fusion protein |
| Application: | ELISA, FC, IF, IHC-P, IHC-Fr, Blk |
3678
ITGA5
P08648
Purified
Recombinant Monoclonal
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.
This antibody binds human α5β1 integrin with high affinity (Kd = 0.367 nM, EC₅₀ = 0.2 nM, IC₅₀ = 2.3 nM) and, in chimeric mouse-human IgG4 form, demonstrated potent anti angiogenic and anti tumor effects in preclinical models (laser induced CNV in cynomolgus monkeys, VX2 carcinoma in rabbits) before progressing into Phase II trials in platinum resistant ovarian cancer (Ramakrishnan et al., 2006, PMID: 17024968; Bhaskar et al., 2007, PMID: 17786386). Exclusive binding to α5β1 (no cross reactivity with α3β1, αvβ3, αvβ5) was confirmed by ELISA. Immunohistochemistry (IHC-F) demonstrated binding to cynomolgus vasculature but not to mouse tissue. Studies with recombinant integrin subunits revealed that binding depends specifically on the human α5 chain, while the β1 chain can be of either human or mouse origin, indicating strict specificity for the α5β1 heterodimer (Bukowski et al., 2009; DOI: 10.1007/978-1-59745-332-5). In clinical testing, weekly 15 mg/kg IV dosing achieved trough serum levels >150 µg/mL, with 2-3x accumulation by Day 50, detectable antibody in ascites, reduction in circulating endothelial progenitor cells, and a favorable safety profile. The use of this antibody in IHC-P was demostrated (Bell McGuinn et al., 2011; PMID: 21276608). Clone F200, a Fab derivative of M200, is available upon request.